First Post-Approval Clinical Use of F-18 Flurpiridaz With Exercise Cardiac PET in the United States.

ABSTRACT:

Background

F-18 flurpiridaz is a novel radiotracer approved for positron emission tmography (PET) myocardial perfusion imaging. Its long half-life supports exercise stress testing, and its short positron range and high myocardial extraction fraction provide superior image resolution.

Early reports summary

A 70-year-old man with known coronary artery disease and prior coronary revascularization underwent exercise cardiac PET with F-18 flurpiridaz for chest discomfort. PET showed ischemia in the left anterior descending and right coronary artery territories. Coronary angiography revealed a severe mid-left anterior descending lesion and a severe proximal lesion in a small-caliber right posterior descending artery.

Discussion

Ischemia on PET correlated with coronary angio

SUBMITTER: Tandon S 

PROVIDER: S-EPMC12540280 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature